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Loss- and gain-of-function mutations in the broadly
expressed gene Lrp5 affect bone formation, causing
osteoporosis and high bone mass, respectively.
Although Lrp5 is viewed as a Wnt coreceptor, osteo-
blast-specific disruption of b-Catenin does not affect
bone formation. Instead, we show here that Lrp5
inhibits expression of Tph1, the rate-limiting biosyn-
thetic enzyme for serotonin in enterochromaffin cells
of the duodenum. Accordingly, decreasing serotonin
blood levels normalizes bone formation and bone
mass in Lrp5-deficient mice, and gut- but not osteo-
blast-specific Lrp5 inactivation decreases bone
formation in a b-Catenin-independent manner. More-
over, gut-specific activation of Lrp5, or inactivation
of Tph1, increases bone mass and prevents ovariec-
tomy-induced bone loss. Serotonin acts on osteo-
blasts through the Htr1b receptor and CREB to
inhibit their proliferation. By identifying duodenum-
derived serotonin as a hormone inhibiting bone
formation in an Lrp5-dependent manner, this study
broadens our understanding of bone remodeling
and suggests potential therapies to increase bone
mass.
INTRODUCTION
Bone remodeling, the physiological means whereby vertebrates
renew their bones during adulthood, comprises two phases: re-
sorption of preexisting mineralized bone matrix by a specialized
cell type, the osteoclast, followed by de novo bone formation
by another specialized cell type, the osteoblast. Over the last
15 years, molecular and genetic studies have identifiednumerous local and systemic regulators of this process and as
a result have considerably improved our molecular understand-
ing of both aspects of bone remodeling (Zaidi, 2007).
One of the most intensively studied regulators of bone
remodeling is LDL-receptor related protein 5 (LRP5) (Baron
and Rawadi, 2007). This interest stems from the fact that LRP5
loss-of-function mutations cause osteoporosis pseudoglioma
(OPPG), a rare disease characterized by severe decreased
bone formation and persistence of embryonic eye vasculariza-
tion leading to low bone mass and blindness (Gong et al., 2001).
Other, presumably activating, mutations in LRP5 cause high
bone mass syndrome (Boyden et al., 2002). That different muta-
tions in this gene cause two bone diseases of opposite nature
underscores the critical importance in the regulation of bone
formation of the pathway(s) controlled by Lrp5.
Lrp5 encodes a broadly expressed cell-surface molecule
sharing sequence homology with Arrow, a coreceptor for the
growth factorWingless inDrosophila (Bhanot et al., 1996). Based
on this sequence homology and, among other evidence, cell-
based assays in which Lrp5 and Axin interaction is initiated by
Wnt proteins, it is assumed that Lrp5 is a coreceptor for Wnt pro-
teins, the vertebrate homologs of Wingless (Tamai et al., 2004).
As a result, OPPG and high bone mass syndrome are viewed
as Wnt-related diseases (Krishnan et al., 2006). Three observa-
tions, however, challenge this view. First, contrasting with the
developmental function of most Wnt proteins, there is no overt
skeletal defect in Lrp5/ embryos. Second, gain-of-function
mutations in Lrp5 do not cause bone tumors as activation of
Wnt signaling does in other organs (Moon et al., 2004). Third
and more importantly, osteoblast-specific loss- and gain-
of-function mutations in b-Catenin (b-Cat), the molecular node
of canonical Wnt signaling, do not affect either bone formation
or expression of genes dysregulated upon Lrp5 inactivation
(Glass et al., 2005). Taken individually, none of these observa-
tions rules out that Lrp5 functions as a Wnt coreceptor to regu-
late bone formation. However, when considered together, weCell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 825
viewed them as an incentive to search for additional/other
mechanisms of action of this gene in osteoblasts.
Serotonin is a bioamine generated in brainstem neurons and
enterochromaffin cells of the duodenum that does not cross
the blood-brain barrier (Mann et al., 1992). Thus, it is de facto
a molecule with two functional identities depending on its site
of synthesis. Whereas brain-derived serotonin is implicated in
cognitive functions (Heath and Hen, 1995), the function(s) of
gut-derived serotonin (GDS), which accounts for 95% of total
serotonin, is still a matter of debate (Gershon and Tack, 2007).
The GDS biosynthetic pathway involves the rate-limiting enzyme
tryptophan hydroxylase 1 (Tph1). GDS is released in the general
circulation, where most of it is taken up by platelets through
a specific transporter (Gershon and Tack, 2007). A small fraction
of it, however, remains free in the serum and may conceivably
act as a hormone following its binding to serotonin receptors
present on target cells (Rand and Reid, 1951). Remarkably,
patients taking synthetic serotonin reuptake inhibitors (SSRIs)
chronically, a class of drugs increasing extracellular serotonin
concentration throughout the body, can have reduced bone
mass (Richards et al., 2007).
While searching for molecular mechanisms explaining Lrp5
regulation of bone formation, we identified Tph1 as the most
highly overexpressed gene in Lrp5/ bones. Tph1 was also in-
creased in Lrp5/ duodenal cells, its primary site of expression.
Inhibiting serotonin synthesis in Lrp5/mice corrects their bone
phenotype, and gut- but not osteoblast-specific deletion of Lrp5
recapitulates the bone phenotype of Lrp5/ mice. The same
pathway is affected, in an opposite manner, in the case of Lrp5
gain-of-function mutation, thus providing a simple molecular
basis for the two diseases. Serotonin, after binding to the Htr1b
receptor, determines the extent of bone formation by controlling
osteoblast proliferation through the regulation of CyclinD1 ex-
pression by CREB. By revealing that Lrp5 regulates bone mass
by inhibiting duodenal synthesis of serotonin, a hormone
decreasing bone formation, this study points toward adapted
therapies for diseases characterized by an impairment of bone
formation.
RESULTS
Molecular Signature of Lrp5 Loss-of-Function Mutation
The different nature of the cellular events leading to a low bone
mass phenotype in Lrp5/ (decrease in bone formation) and
b-Cat(ex3)osb
/ (decrease in bone resorption) mice suggested
that distinct molecular mechanisms were at work in these two
models. Thus, in an effort to elucidate how Lrp5 regulates
bone formation, we looked for a specific molecular signature
of Lrp5 loss-of-function mutation in bone in vivo. For that
purpose, we analyzed the expression of genes affecting either
cell proliferation (Cyclins), osteoblast differentiation (Runx2,Osx,
Atf4), bone matrix deposition (Type I Collagen), or osteoclast dif-
ferentiation (Osteoprotegerin, RankL) in wild-type, Lrp5/, and
b-Cat(ex3)osb
/ bones. The only genes whose expression was
decreased in Lrp5/ bones were the regulators of cell prolifera-
tion CycD1, D2, and E1 (Figure 1A). Consistent with the fact that
osteoblast number is normal in b-Cat(ex3)osb
/ mice, expres-
sion of the Cyclin genes was not affected in b-Cat(ex3)osb
/826 Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc.bones; conversely, genes whose expression was affected in
b-Cat(ex3)osb
/ bones were normally expressed in Lrp5/
bones (Figure 1A).
In striking contrast to the paucity of osteoblasts present in
Lrp5/ bones (Kato et al., 2002), Lrp5/ osteoblasts prolifer-
ated as well as WT cells ex vivo (Figure 1B). We interpreted the
discrepancy between the in vivo and ex vivo proliferation abilities
of the Lrp5/ osteoblasts as indicating that Lrp5 loss-of-
function mutations affect osteoblast proliferation through extra-
cellular signals that may not originate from osteoblasts, in other
words that Lrp5-related bone diseases may not originate from
bones.
As a first attempt to test the aforementioned hypothesis, we
reanalyzed results of a microarray experiment performed earlier
(Glass et al., 2005). The gene most highly expressed in Lrp5/
compared to WT bones was Tph1, which encodes an enzyme
initiating synthesis outside the brain of serotonin, a secreted
molecule that may affect bone mass (Warden et al., 2005)
(Figure 1C). Real-time PCR analysis verified that Tph1was over-
expressed in Lrp5/ osteoblasts and bones (Figure 1D). Tph1 is
predominantly expressed in duodenum in WT mice and it
was also vastly overexpressed in this organ in Lrp5/ mice,
where its expression was 1500-fold higher than in osteoblasts
and 150-fold higher than in any other part of the gastrointestinal
tract (Figures 1E and 1F). Tph1 expression was not affected in
b-Cat(ex3)osb
/ bones, further differentiating Lrp5 and canoni-
calWnt signaling regulations of bonemass (see Figure S1A avail-
able online). In contrast, neither expression of Tph2, the enzyme
initiating serotonin synthesis in the brain, nor brain serotonin
content was affected in Lrp5/ mice (Figures S1B and S1C).
This latter observation is consistent with the notion that serotonin
does not cross the blood-brain barrier (Mann et al., 1992).
Multiple correlative evidence suggested that this increase in
Tph1 expression is implicated in the development of the Lrp5/
mice bone phenotype. First, Tph1 expression was normal in
newborn Lrp5/mice that do not display overt bone abnormal-
ities but increased steadily thereafter (Figures 1G, S1D, and
S1E). A significant increase in Tph1 expression was first de-
tected at 2 weeks of age, that is, 2 weeks before the low bone
mass phenotype becomes apparent in Lrp5/mice. Consistent
with this increase in Tph1 expression, blood serotonin levels in-
creased as a function of time in Lrp5/ mice (Figure 1H). This
large increase in blood serotonin levels was not due to more
platelets in Lrp5/mice (Figure S1F). Second, Tph1 expression
and blood serotonin levels were increased in Lrp5+/ mice that
also have a low bone mass (Figures 1G and 1H). Third, there
was in three OPPG patients tested (Gong et al., 2001; Toomes
et al., 2004) a 4- to 5-fold increase in circulating serotonin levels
when compared to age-matched controls; moreover, the hetero-
zygous parent of one of these patients also had higher circulating
serotonin levels than control individuals (Figures 1I and S1G).
Thus, Lrp5 regulates blood serotonin level in both mice and
humans.
Increased Circulating Serotonin Level as a Determinant
of the Lrp5/ Mice Bone Phenotype
To determine whether the increase in circulating serotonin level
induced by the increase in Tph1 expression is a cause of the
Figure 1. Increased Tph1 Expression and Serum Serotonin Levels in Lrp5/ Mice
(A) Real-time PCR analysis of gene expression in WT, Lrp5/, and b-Cat(ex3)osb
/ bones.
(B) Proliferation analysis (BrdU labeling) in vivo and ex vivo of WT and Lrp5/ osteoblasts.
(C) Microarray analysis of WT and Lrp5/ bones.
(D) Increased Tph1 expression in osteoblasts (Osb) and bones of Lrp5/ mice by real-time PCR analysis.
(E and F) Real-time PCR analysis of Tph1 expression in tissues of WT and Lrp5/ mice (E), and in primary osteoblasts (Osb) and gut of WT mice (F).
(G and H) Real-time PCR analysis of Tph1 expression in gut versus bone (G), and serum serotonin levels (H) in WT, Lrp5+/, and Lrp5/mice at indicated ages.
(I) Serum serotonin levels in two OPPG patients and age-matched controls (n = 6).
Results are given as means ± standard deviations (SDs). Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT
or control.bone phenotype of the Lrp5/mice, we relied on cell-based and
in vivo experiments.
To elucidate the discrepancy between the paucity of osteo-
blasts in Lrp5/ bones but their normal proliferation ability ex
vivo, we tested whether serotonin is an inhibitor of osteoblast
proliferation. When treated with serotonin for 24 hr, proliferation
of WT or Lrp5/ osteoblasts was decreased to the same extent
(Figure 2A); in contrast, Wnt3A-conditioned media did not affect
osteoblast proliferation (Figure S2F). Serotonin decreased ex-
pression of CycD1, D2, and E1 without affecting expression of
Type I Collagen or of other genes characteristic of the osteoblast
phenotype (Figures 2B and S2A), a gene expression profile re-
markably similar to the one seen in the Lrp5/ bones (Figure 1A).
To further determine whether serotonin inhibits osteoblastproliferation in a Wnt-dependent or -independent manner,
we treated ROS17 osteoblastic cells transfected with the
TOPFLASH reporter construct with increasing amounts of
serotonin or, as a positive control, with lithium chloride (LiCl)
(Clement-Lacroix et al., 2005). Whereas LiCl increased the activ-
ity of this reporter vector in all experiments, serotonin always
failed to do so, indicating that the serotonin and canonical Wnt
signaling pathways are distinct in osteoblasts (Figure 2C).
If the increase in blood serotonin level is a cause of the Lrp5/
mice bone phenotype, then normalizing it should also normalize
bone mass in these mice. To test this hypothesis, we performed
two in vivo experiments. Because serotonin is a tryptophan
derivative, we first fed WT and Lrp5/mice from 3 to 12 weeks
of age a diet containing 75% less tryptophan than a normal diet.Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 827
Figure 2. Serotonin Inhibits Osteoblast Proliferation, and Decreasing Serum Serotonin Levels Correct Lrp5/ Mice Bone Phenotype
(A) Ex vivo proliferation rates of WT and Lrp5/ osteoblasts treated with serotonin (50 mM) for 24 hr.
(B) Real-time PCR analysis of Cyclins and Col1a1 expression in WT osteoblasts treated with serotonin (50 mM) for 24 hr.
(C) TOPFLASH reporter activities in osteoblasts in response to serotonin (10–50 mM) or lithium chloride (LiCl, 10 mM).
(D and E) Serum serotonin levels (D) and histological analysis of vertebrae (E) of WT and Lrp5/mice fed a normal diet or a 75% tryptophan-less diet. Mineralized
bone matrix is stained in black by von Kossa reagent. Histomorphometric parameters: BV/TV, bone volume over trabecular volume; Nb.Ob/T.Ar., number of
osteoblasts per trabecular area; BFR, bone formation rate; OcS/BS, osteoclast surface per bone surface.
(F–H) Serum serotonin levels (F), real-time PCR analysis ofCyclin expression in bone (G), and histomorphometric analyses (H) inWT and Lrp5/mice treatedwith
the serotonin synthesis inhibitor pCPA (100 mg/kg).
Results are given as means ± SDs. Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.This reduction in tryptophan intake decreased circulating seroto-
nin levels 8- to 10-fold without affecting serotonin brain content
(Figures 2D and S2B) and normalized bone formation parame-
ters and bone mass in Lrp5/ mice (Figure 2E). Second,
4-week-old WT and Lrp5/ mice were administered para-
chlorophenylalanine (pCPA), a drug inhibiting serotonin
synthesis, for 8 weeks (Kubera et al., 2000). pCPA decreased
circulating serotonin levels 5- to 7-fold in Lrp5/ mice without
affecting their serotonin brain content; it also normalized in
Lrp5/ mice bone mass, bone formation parameters, and828 Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc.Cyclin expression in bones (Figures 2F–2H and S2C). That
pCPA did not induce regression of the hyaloid vessels in the
eyes suggests that the eye phenotype of the Lrp5/ mice is
not caused by this increase in circulating serotonin levels
(Figures S2D and S2E).
Taken together, results of the cell biology experiments of the
low tryptophan diet and the pCPA-induced serotonin depletion
in WT and Lrp5/ mice indicate that higher blood serotonin
levels contribute to the decrease in bone formation and bone
mass in Lrp5/ mice.
Figure 3. Lrp5 Regulates Serotonin Synthesis through Its Expression in Gut
(A and B) Real-time PCR analysis of Lrp5 (A) and Tph1 (B) expression in the gut and long bones (Bone) of Lrp5gut
/ and Lrp5osb
/ compared to +/+;Villin-Cre
and +/+;a1(I)Col-Cre mice, respectively.
(C) Serum serotonin levels in +/+;Villin-Cre, Lrp5gut
/, +/+;a1(I)Col-Cre, and Lrp5osb
/ mice.





(E) Real-time PCR analysis of Cyclins and Col1a1 expression in long bones of WT, Lrp5gut
/, and Lrp5osb
/ mice.
(F) In vivo osteoblast proliferation in WT, Lrp5gut
/, and Lrp5osb
/ mice.
(G) Western blot analysis of Lrp5 high bone mass (G171V) cDNA expression (Flag) in bone and gut of Lrp5KIosb
+/ and Lrp5KIgut
+/ compared to +/+;a1(I)Col-Cre
and +/+;Villin-Cre mice, respectively.
(H and I) Real-time PCR analysis of Tph1 expression (H) in the gut and long bones (Bone) and serum serotonin levels (I) in Lrp5KIosb
+/ and Lrp5KIgut
+/ compared
to +/+;Villin-Cre and +/+;a1(I)Col-Cre mice, respectively.




(L) Plasma serotonin levels in two high bone mass (HBM) patients and age-matched controls (n = 3).
Results are given as means ± SDs. Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.Lrp5 Regulates Serotonin Synthesis and Bone
Formation through Its Duodenal Expression
In light of these results, we next asked whether Lrp5 regulates
Tph1 expression, serotonin synthesis, and bone formation
through its duodenal or its osteoblast expression. To that end,
we generated mice harboring a floxed loss-of-function allele of
Lrp5 (Figures S3A and S3B) and crossed them with either
Villin-Cre transgenic mice to delete Lrp5 from gut cells
(Lrp5gut
/) or with a1(I)Col-Cre transgenic mice to delete it
from osteoblasts only (Lrp5osb
/) (Dacquin et al., 2002; el
Marjou et al., 2004). Real-time PCR analysis demonstrated that
efficient recombination occurred in duodenal cells but not in os-
teoblasts in the Lrp5gut
/ mice, whereas the opposite was true
in the Lrp5osb
/ mice (Figures 3A and S3C). Tph1 expression
was high in the gut and normal in osteoblasts in Lrp5gut
/mice; the opposite was true in the Lrp5osb
/ mice (Figure 3B).
Circulating serotonin levels were 5- to 8-fold higher in Lrp5gut
/
than in WT mice but remained normal in Lrp5osb
/ mice
(Figure 3C). In both mutant mice, brain serotonin content was
normal (data not shown).
Histomorphometric analyses showed a decrease in bone
mass in Lrp5gut
/ but not in Lrp5osb
/ mice (Figure 3D). This
low bone mass was secondary to a decrease in osteoblast num-
bers and bone formation whereas osteoclast numbers were not
affected (Figure 3D). Expression of CycD1, D2, and E1 was
decreased in the bones of Lrp5gut
/ mice but was unaffected
in Lrp5osb
/ bones, and BrdU incorporation assays showed
that osteoblast proliferation was decreased in Lrp5gut
/ but
not in Lrp5osb
/mice (Figures 3E and 3F). Thus, gut- but not os-
teoblast-specific deletion of Lrp5 recapitulates the low boneCell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 829
mass and the molecular abnormalities observed in the Lrp5/
mice. As is the case for Lrp5+/ mice, Lrp5gut
+/ mice displayed
a low bone formation/low bone mass phenotype (Figure S3D).
These data suggest that Lrp5 regulates bone formation through
its duodenal expression. In contrast, histological examination
failed to detect any persistence of hyaloid vessels of the eyes
in either Lrp5gut
/ or Lrp5osb
/ mice (Figure S3E). This latter
result, along with the inability of pCPA to prevent appearance
of the eye phenotype in the Lrp5/ mice, demonstrates that
Lrp5 uses different mechanisms to regulate bone formation
and eye vascularization.
Duodenal-Specific Lrp5-Activating Mutation Causes
High Bone Mass
The demonstration that Lrp5 loss of function affects bone mass
by enhancing serotonin synthesis in the enterochromaffin cells
raised the prospect that, conversely, Lrp5 gain-of-function
mutations might affect bone mass by decreasing serotonin syn-
thesis in these cells. To test this hypothesis, we generated mice
harboring a floxed allele of Lrp5 that included the mutation caus-
ing high bone mass in humans (Boyden et al., 2002) (Figures S3F
and S3G). These mice were crossed with either Villin-Cre or
a1(I)Col-Cre transgenic mice to generate mice expressing this
Lrp5 gain-of-function mutation in gut cells (Lrp5KIgut
+/) or in
osteoblasts (Lrp5KIosb
+/). We studied heterozygous mutant
mice because high bone mass syndrome is observed in patients
heterozygous for the mutation (Boyden et al., 2002).
Lrp5KIgut
+/mice expressed themutated protein in gut but not
in osteoblasts; the opposite was true for Lrp5KIosb
+/ mice
(Figure 3G, S3H, and S3I). Tph1 expression in gut and circulating
serotonin levels were low in Lrp5KIgut
+/mice (Figures 3H and 3I)
whereas serotonin content in the brain was not affected (data
not shown). Histomorphometric analyses showed that bone
formation parameters and bone mass were high in Lrp5KIgut
+/
but normal in Lrp5KIosb
+/ mice (Figure 3D). Expression of
Cyclins and in vivo osteoblast proliferation were increased in
Lrp5KIgut
+/ bones; none of these parameters were modified in
Lrp5KIosb
+/mice (Figures 3J, 3K, and S3J). To validate our find-
ings obtained in mice, we studied two patients with high bone
mass caused by the same activating mutation (G171V) in LRP5
(Boyden et al., 2002) and observed a 50%decrease in circulating
serotonin levels (Figure 3L).
In summary, based on the analyses of cell-specific loss- and
gain-of-function mutations of Lrp5 models, it appears that this
gene regulates bone formation through its duodenal but not its
bone expression.
Gut-Derived Serotonin Regulates Bone Formation
To further demonstrate that it is duodenal-derived serotonin that
regulates bone formation, we generated mice harboring a floxed
loss-of-function allele of Tph1 and crossed them with Villin-Cre
or a1(I)Col-Cre mice to generate Tph1gut
/ or Tph1osb
/ mice
(Figures S4A–S4C). Because Tph1 is overexpressed in Lrp5/
mice, its deletion in the appropriate cell type should result in
a bone phenotype opposite the one of the Lrp5/ mice (i.e.,
high bone mass). Tph1gut
/ mice had a 10-fold reduction in
Tph1 expression in gut, whereas Tph1 expression in bone and
osteoblasts was not affected; conversely, Tph1osb
/ mice had830 Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc.a 10-fold reduction in Tph1 expression in bones and osteoblasts
but a normal Tph1 expression in gut (Figures 4A and 4B). Circu-
lating serotonin levels were low in Tph1gut
/ but normal in
Tph1osb
/ mice (Figure 4C).
As anticipated, mice lacking Tph1 in the gut developed a
severe high bone mass phenotype secondary to an increase in
osteoblast number and bone formation rate; bone resorption
parameters were not affected (Figure 4D). This phenotype, that
is the mirror image of the one seen in the Lrp5/ mice, was
present in 4-, 6-, and 12-week-old Tph1gut
/ mice (Figures 4D
and S4D). In contrast, mice lacking Tph1 in osteoblasts had
only amarginal, nonsignificant increase in bonemass (Figure 4E).
Expression of CycD1, D2, and E1, which was decreased in
the absence of Lrp5, was increased in Tph1gut
/ but normal in
Tph1osb
/ bones, and BrdU incorporation assays showed that
osteoblast proliferation was increased in Tph1gut
/ but not in
Tph1osb
/ mice (Figures 4F and 4G).
The Htr1b Receptor Mediates Serotonin Regulation
of Osteoblast Proliferation
If circulating serotonin is a hormone inhibiting bone formation, it
must act through a specific receptor(s) present on osteoblasts
whose inactivation should lead to an increase in bone formation
and high bone mass.
Among the 14 known serotonin receptors, only 3 are ex-
pressed in osteoblasts: Htr1b, the most highly expressed,
Htr2b, and Htr2a (Figure 5A). Htr1b is preferentially expressed
in bone and osteoblasts outside the brain, whereas Htr2b and
Htr2a have a broader pattern of expression (Figures 5B and
S5A). Analysis of Htr2a/ mice failed to detect any abnormali-
ties in osteoblast number, bone formation, bone resorption,
and bone mass at 1 or 3 months of age (Figures 5C and S5B),
two time points at which Lrp5/ mice already display a severe
bone phenotype. The same was true for mice lacking in osteo-
blasts only, Htr2b (Figures 5D and S5B–S5E). In contrast, mice
lacking either one or the two Htr1b alleles displayed a similar
increase in osteoblast number, bone formation rate, and bone
mass at those ages (Figures 5E and S5B). That haploinsuffi-
ciency atHtr1b has consequences as severe as the homozygous
deletion, at least at 6weeks of age, is consistent with the fact that
heterozygous loss-of-function mutation in Tph1 or heterozygous
gain-of-function mutation in Lrp5 also have consequences as
severe on bone mass as homozygous mutations. Furthermore,
it is also in accord with the observation that patients with high
bonemass are only heterozygous for Lrp5mutations. Altogether,
it demonstrates that loss of serotonin signaling exerts a dominant
function on bone remodeling. Molecularly, expression of
CycD1, D2, and E1 that is downregulated in Lrp5/ bones
was upregulated in Htr1b/ but not in Htr2a/ or Htr2bosb
/
bones, and serotonin treatment decreased CycD1 expression
in WT,Htr2a/, and Htr2bosb
/ but not in Htr1b/ osteoblasts
(Figures 5F and 5G). BrdU incorporation assays confirmed that
osteoblast proliferation was increased in Htr1b/ but not in
Htr2a/ and Htr2bosb
/ bones (Figure 5H). Other osteoblast-
specific genes such as Osteoprotegerin, a Wnt target gene
(Glass et al., 2005), were normally expressed in Htr1b/ bones,
further differentiating canonical Wnt and serotonin signaling
pathways in osteoblasts (Figure S5F).
To ascertain that Htr1b regulates bone formation through its
expression in osteoblasts, we generated mice lacking Htr1b
only in osteoblasts (Htr1bosb-deficient mice; Figures S5G and
S5H). As shown in Figure 5I, Htr1bosb
+/ mice display the same
high bone formation/high bone mass phenotype as the one
observed in the Htr1b+/ mice. Taken together, these results
indicate that serotonin uses one predominant receptor, Htr1b,
to affect osteoblast biology.
Serotonin Regulates Osteoblast Proliferation
through CREB
We next searched for the transcriptional mediator(s) of serotonin
signaling in osteoblasts. To address this question, because loss-
of-function mutations in most of the key transcription factors
governing osteoblast differentiation are embryonic lethal, we
generated compound mutant mice lacking one allele of Lrp5
and one allele of each transcription factor of interest. We rea-
soned that if Lrp5 and a particular transcription factor are in
the same genetic cascade, compound heterozygous mice may
reproduce the bone phenotype of the Lrp5/ mice. Removing
one allele of Runx2 or Osx from Lrp5+/ mice did not worsen
the bone phenotype of these latter mutant mice, a result consis-
Figure 4. Duodenal-Derived Serotonin Regulates
Bone Formation
(A and B) Real-time PCR analysis of Tph1 expression in the gut
and long bones (Bone) and Tph2 expression in the brainstem
(BS) of Tph1gut
/ and Tph1osb
/ compared to +/+;Villin-Cre
and +/+;a1(I)Col-Cre mice, respectively.
(C–E) Serum serotonin levels (C) and bone histomorphometric




(F) Real-time PCR analysis of Cyclins and Col1a1 expression
in long bones of WT, Tph1gut
/, and Tph1osb
/ mice.




Results are given as means ± SDs. Statistical analysis was
performed by Student’s t test. For all panels, *p < 0.05 and
**p < 0.01 versus WT or control.
tent with the normal expression of Runx2 and Osx
in Lrp5/ osteoblasts (Figure 1A). These observa-
tions strongly suggest that neither of these two
factors act downstream of serotonin (Figures 6A
and S6).
Because Htr1b is linked to the Gai protein that in-
hibits cAMP production and PKA-dependent phos-
phorylation (Heath and Hen, 1995), we studied
transcription factors that, like CREB, are phosphor-
ylated by PKA. Removing one allele of Atf4,
a CREB-related osteoblast-enriched transcription
factor (Yang et al., 2004), from Lrp5+/ mice did
not affect the bone phenotype of these latter
mice, arguing against a role for ATF4 in mediating
serotonin signaling in osteoblasts (Figures 6A and
S6). In contrast, compound mutant mice lacking
one allele of Lrp5 and, in osteoblasts only, one
allele of Creb displayed a low bone formation/low
bone mass phenotype indistinguishable from the
one observed in the Lrp5/mice (Figures 6A and S6). This result
suggested that CREB is amajor transcriptional mediator of sero-
tonin signaling in osteoblasts. In support of this contention, sero-
tonin treatment of primary osteoblasts decreased phosphoryla-
tion of CREB on Ser133, the target of PKA, in WT but not in
Htr1b/ cells (Figure 6B) and abolished binding of CREB to
the promoter ofCycD1, a known target gene of CREB (Figure 6C)
(Fu et al., 2005). That CycD1 expression is decreased in
Crebosb
+/ but not in Atf4+/mice, used here as a negative con-
trol, is in full agreement with the ex vivo assays presented above
(Figure 6D). Furthermore, thatCreb expression was decreased in
Lrp5gut
/ long bones, increased in Lrp5KIgut
+/ long bones, but
unaffected in either Lrp5osb
/ or Lrp5KIosb
+/ long bones
(Figure 6E) raises the prospect that serotonin regulates Creb
expression in vivo.
Genetic Validation of the Interactions between Lrp5,
Tph1, Htr1b, and Creb
To demonstrate that the gut-derived serotonin/osteoblast/CREB
pathway described here mediates Lrp5-dependent regulation of
osteoblast proliferation and bone formation, we generated vari-
ous compound mutant mice. First, we showed that mutantCell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 831
Figure 5. Serotonin Inhibits Osteoblast Proliferation through Htr1b
(A and B) Real-time PCR analysis of serotonin receptor expression in primary osteoblasts (A) and of Htr1b expression in different tissues of WT mice (B).
(C–E) Histomorphometric analysis of vertebrae of 3-month-old WT, Htr2a/ (C), Htr2bosb
/ (D), and Htr1b/ (E) mice.
(F) Real-time PCR analysis of Cyclins, Runx2, Osx, and Atf4 expression in long bones of WT, Htr1b/, Htr2a/, and Htr2bosb
/ mice.
(G) Real-time PCR analysis of CycD1 expression in primary osteoblasts of WT, Htr1b/, Htr2a/, and Htr2bosb
/ mice treated with serotonin (50 mM).
(H) In vivo osteoblast proliferation in WT, Htr1b/, Htr2a/, and Htr2bosb
/ mice.
(I) Histomorphometric analysis of vertebrae of 6-week-old WT and Htr1bosb
+/ mice.
Results are given as means ± SDs. Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.mice lacking one allele ofHtr1b and one allele of Tph1 in gut cells
developed the same high bone mass phenotype as Htr1b/ or
Tph1gut
/mice (Figures 7A and S7A). Moreover, removal of one
allele ofCreb, in an osteoblast-specificmanner, from theHtr1b/
mice rescued the increase in bone formation parameters and the
high bone mass of these mutant mice (Figures 7A and S7A).
These experiments indicated that Tph1 in gut cells, and Htr1b
and Creb in osteoblasts, are in the same genetic cascade regu-
lating bone formation. Next, to ascertain that Tph1 in the gut and
Htr1b mediate Lrp5-dependent regulation of bone mass, we
removed from the Lrp5/ mice one allele of Tph1 in gut cells832 Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc.or one allele of Htr1b (Figures 7A and S7A). Both these manipu-
lations could normalize the bone abnormalities observed in the
Lrp5/mice, indicating that serotonin synthesis in duodenal en-
terochromaffin cells and serotonin binding to Htr1b are down-
stream of Lrp5 (Figures 7A and S7A). Thus, the results presented
in this study indicate that the main mechanism whereby Lrp5
favors bone formation and bone mass accrual is by inhibiting
Tph1 expression in and serotonin synthesis by enterochromaffin
cells of the gut. Serotonin in turn prevents bone formation follow-
ing its binding to Htr1b by inhibiting Creb expression and
function, CycD1 expression, and osteoblast proliferation.
Figure 6. Lrp5 Mediates Its Effect through CREB
(A) Histomorphometric analysis of vertebrae of WT and single (Lrp5+/, Runx2+/, Osx+/, Atf4+/, or Crebosb
+/) and double (Lrp5+/;Runx2+/, Lrp5+/;Osx+/,
Lrp5+/;Atf4+/, or Lrp5+/;Crebosb
+/) heterozygous mutant mice.
(B and C) Western blot analysis of CREB phosphorylation (B) and chromatin immunoprecipitation assay of CREB binding to the consensus cAMP response
element (CRE) in the CycD1 promoter (C) at 0, 3, 6, 12, and 24 hr upon serotonin (50 mM) treatment. Coding sequence (CDS) PCR, IgG pull-down, and ATF4
binding to the same site were used as negative controls.
(D) Real-time PCR analysis of CycD1 expression in the long bones of WT, Lrp5+/, Lrp5/, Crebosb
+/, Osx+/, and Runx2+/ mice.





Results are given as means ± SDs. Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.Lrp5 and b-Cat Expression in Gut and Bone Mass
Because Lrp5 has been proposed to be a Wnt coreceptor, we
next asked whether it was regulating Tph1 expression in a
b-Cat-dependent or -independent manner. To that end, we
generated mice lacking one allele of Lrp5 and one allele of
b-Cat in gut cells (Figures S7B and S7C), reasoning that if Lrp5
and b-Cat were in the same genetic pathway then these
compound heterozygous mice should have the same low bone
formation and low bone mass phenotype as the Lrp5/ mice.
This strategy has been used by us to demonstrate genetic inter-
action between b-Cat and other genes in osteoblasts (Glass
et al., 2005).
As shown in Figure 7B, whereas Lrp5+/mice had a low bone
formation and low bone mass phenotype, b-Catgut
+/ mice did
not; more importantly, the compound heterozygous Lrp5+/;
b-Catgut
+/ did not have a more severe low bone formation and
low bone mass than the Lrp5+/ mice. Molecularly, there was
no change in Tph1 expression in the gut and in serum serotonin
levels in b-Catgut
+/ compared to WT mice (Figure 7C). We also
generated compound mutant mice lacking one allele of Tph1
and one allele of b-Cat in gut. Here again, we did not see in
Tph1gut
+/;b-Catgut
+/ any worsening of the bone phenotype
observed in the Tph1gut
+/ mice (Figure 7B). Because of their
negative nature, these results have to be interpreted cautiously,
yet that b-Cat haploinsufficiency can in other cell types lead tophenotypic abnormalities strongly suggests that Lrp5 regulates
Tph1 expression and serotonin synthesis independently of
b-Cat expression in gut (Glass et al., 2005).
Decreasing Duodenal Serotonin Synthesis Protects
Mice from Ovariectomy-Induced Bone Loss
To assess the biological importance of the serotonin regulation
of bone mass, we tested whether the increase in bone formation
parameters observed in Tph1gut
/ mice was sufficient to pro-
tect them from ovariectomy-induced bone loss. WT and
Tph1gut
/were ovariectomized (Ovx) at 6 weeks of age and an-
alyzed at 3 months of age. Histomorphometric analyses showed
an increase in bone resorption parameters in both WT and
Tph1gut
/ mice following Ovx (Figure 7D). Nevertheless,
whereas Ovx WT mice developed a low bone mass phenotype,
Ovx Tph1gut
/mice still harbored a high bone mass phenotype
which was due to their increase in bone formation parameters
(Figure 7D). Thus, decreasing serotonin production in entero-
chromaffin cells of the gut protects mice from ovariectomy-
induced osteoporosis.
DISCUSSION
This study uncovers an unanticipated molecular mechanism ac-
counting for the Lrp5 regulation of bone formation; our findingsCell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 833
Figure 7. Genetic Interaction between Lrp5 and Serotonin
(A) Bone histomorphometric analysis (vertebrae) of WT, Htr1b+/, Tph1gut
+/, Htr1b+/;Tph1gut
+/, Lrp5/, Lrp5/;Htr1b+/, and Lrp5/;Tph1gut
+/ mice.
(B) Bone histomorphometric analysis (vertebrae) of WT, b-Catgut
+/, Tph1gut
+/;b-Catgut
+/, Lrp5+/, and Lrp5+/;b-Catgut
+/ mice.
(C) Serum serotonin levels and real-time PCR analysis of Tph1 expression in the gut of WT and b-Catgut
+/ mice.
(D) Bone histomorphometric analysis (vertebrae) of WT, WT(Ovx), Tph1gut
/, and Tph1gut
/ (Ovx) mice.
(E) Model of the Lrp5-dependent regulation of bone formation. Lrp5 favors bone formation and bone mass accrual by inhibiting Tph1 expression and serotonin
synthesis in enterochromaffin cells. Following its binding to Htr1b, serotonin inhibits Creb expression and function, which results in a decrease in CycD1 expres-
sion and osteoblast proliferation.
Results are given as means ± SDs. Statistical analysis was performed by Student’s t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.shift the emphasis from a paracrine to an endocrine regulation of
bone mass, and from bone cells to enterochromaffin cells of the
gut (Figure 7E). Moreover, given the cell-specific expression of
Tph1, this study points toward novel therapeutic avenues for
diseases characterized by a relative or absolute decrease in
bone formation.
Lrp5-Dependent Serotonin Synthesis in the Gut
and Regulation of Bone Formation
Regardless of the mode of action of Lrp5, a hallmark of Lrp5/
bones is a paucity of osteoblasts, a feature contrasting strikingly
with the fact that Lrp5/ osteoblasts proliferate normally ex
vivo. One possible explanation of this discrepancy could be
that osteoblast proliferation in the Lrp5/ mice is affected by
an extracellular signal that is not originating from osteoblasts
themselves.834 Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc.In full support of the hypothesis that the extracellular signal
regulating osteoblast proliferation in the absence of Lrp5 does
not emanate from osteoblasts, cell-specific gene inactivation
or gain-of-function studies established that it is through its
expression in enterochromaffin cells of the gut and not through
its expression in osteoblasts that Lrp5 controls Tph1 expression,
serotonin synthesis, osteoblast proliferation, and bone forma-
tion. The differences in the severity of the bone phenotype
observed in Tph1gut
/ and Lrp5KIgut
+/mice raises the hypoth-
esis that Lrp5 regulates expression in enterochromaffin cells of
other gene(s) regulating bone mass. Last, we cannot rule out
that Lrp5 may exert an autocrine function in osteoblasts that
was not detectable in the genetic manipulations performed
here. By showing that OPPG and high bone mass syndrome
are more gut- than bone-originating diseases, these results put
new light on these two conditions. This work does provide an
explanation for the osteoporosis often observed in patients
with autism who have high blood serotonin levels (Hediger et al.,
2008); however, it does not explain why patients taking SSRIs
chronically often develop osteoporosis (Richards et al., 2007).
LRPs, Bone Remodeling, and Canonical Wnt Signaling
Lrp5 is a member of the family of lipoprotein receptor related
proteins (Lrps), a small group of single-pass transmembrane
proteins (Tamai et al., 2000). Lrp5 has a significant degree of se-
quence homology with the Drosophila protein Arrow, a Wingless
coreceptor (Pinson et al., 2000; Tamai et al., 2004). Based on this
sequence homology and multiple forced expression experi-
ments in cell culture and in vivo, it has been assumed that Lrp5
is a coreceptor for Wnt proteins, the mammalian homologs of
Wingless, and that it is in this capacity that it regulates bone
formation (Gong et al., 2001; Kato et al., 2002).
However, at the present time, all in vivo evidence available
indicates that Lrp5 regulates gut-derived serotonin production
and bone formation in a canonical Wnt signaling pathway-inde-
pendent manner. First, expression of classical Wnt target genes
is normal in Lrp5/ mice gut (Figure S7D); second, serotonin
does not affect the activity of a TOPFLASH reporter construct
or the expression of Osteoprotegerin in osteoblasts, nor does it
affect osteoclast differentiation as b-Cat inactivation does




+/ mice show the bone phenotype of
Lrp5/ or Tph1gut
/ mice, respectively, indicating that Lrp5
and Tph1 on one hand and b-Cat on the other hand are not acting
in the same pathways. It has been shown before that LiCl could
correct the bone phenotype of the Lrp5/ mice (Clement-
Lacroix et al., 2005). This does not necessarily contradict this
contention, because LiCl does not act exclusively onWnt signal-
ing and can affect many pathways in cells including serotonin in
the brain, where its function, if any, in regulating bone mass is for
now unknown (Basselin et al., 2005).
The homology of Arrow with Lrp5 extends to other Lrp
proteins. Indeed, the closest Lrp5 relative, Lrp6, also has
a high degree of homology with Arrow. This is important,
because all genetic evidence obtained before the function of
Lrp5 during bone formation was discovered suggested that
Lrp6 was a better candidate than Lrp5 to be a Wnt coreceptor.
For instance, Lrp6 but not Lrp5 is required for Wnt signaling in
Xenopus and in mice (Pinson et al., 2000; Tamai et al., 2004;
Wehrli et al., 2000). Likewise, Wnt proteins fused to Frizzled
could interact with Lrp6 but not with Lrp5 to activate a Wnt-
responsive reporter gene (Holmen et al., 2002), Lrp6 inactivation
affects embryonic development whereas Lrp5 inactivation does
not (Pinson et al., 2000), and, more decisively, Lrp6 inactivation
affects bone resorption in a TCF-dependent manner like b-Cat
osteoblast-specific inactivation does but does not impair bone
formation as Lrp5 loss-of-function mutation does (Glass et al.,
2005; Kato et al., 2002; Kubota et al., 2008).
Our results do not rule out, however, that Lrp5, in other organs
and/or in cell types other than osteoblasts, may transduce aWnt
signal. In particular, that the eye phenotype of the Lrp5/mice is
not observed in the case of a duodenal- and osteoblast-specific
deletion of Lrp5 and is not corrected by decreasing extracellular
serotonin concentration rules out a serotonin involvement in this
abnormality. This observation provides indirect support toprevious work showing an involvement of Lrp5 in Wnt signaling
in that case (Lobov et al., 2005).
Serotonin Signaling in Osteoblasts
Three serotonin receptors are expressed in osteoblasts. Two of
them, Htr2b and Htr2a, are broadly expressed whereas Htr1b is,
outside the brain, a fairly osteoblast-enriched gene. According to
gene deletion experiments, Htr1b is the receptor responsible for
the effect of serotonin on osteoblasts, whereas inactivation of
either Htr2b or Htr2a does not affect bone mass. Our results
regarding Htr2b are different from those of Collet et al. (2008).
However, in their case, the bone phenotype was observed in
mice lacking the gene in all cells, whereas in our case Htr2b
was deleted only in osteoblasts. Thus, our results relate more
tightly to the function (or lack) of this gene in osteoblasts. It is
possible that the low bone mass phenotype they noted in the
classical Htr2b/ mice could be secondary to the decrease in
heart function observed in these mice (Nebigil et al., 2000).
Until recently, the prevailing view of the transcriptional control
of osteoblast biology is that it involves one of three players that
are osteoblast specific: Runx2, Osx, and ATF4. Yet, none of
these three transcription factors appears implicated in serotonin
signaling in osteoblasts. Instead, CREB, a factor already known
to affect osteoblast proliferation but that is broadly expressed
(Fu et al., 2005), is the main transcriptional effector of serotonin
signaling in osteoblasts. This observation, along with the emerg-
ing role in osteoblasts of other transcription factors such as,
among others, Schnurri-3 or FOXO that are not osteoblast spe-
cific (Jones et al., 2006; Manolagas and Almeida, 2007), suggest
that besides cell-specific transcription factors, other ones, more
broadly expressed, will influence significantly differentiation and/
or functions of the osteoblasts.
The demonstration that Lrp5 belongs to a novel endocrine axis
regulating bone formation illustrates the power of an integrative
approach to bone physiology. It also raises additional questions.
For instance and from a biological point of view, we do not know
yet how Lrp5 expression affects Tph1 expression in enterochro-
maffin cells of the gut. The structure of the Lrp5 protein raises the
prospect that it may be a signaling receptor for a yet to be
identified serotonin synthesis-inhibiting molecule. From a thera-
peutic point of view, the fact that ovariectomized Tph1gut
/
mice do not display bone loss holds great promise given Tph1
cell-specific expression. Further experiments will be needed to
determine whether pharmacologically inhibiting Tph1 or use of
a selective peripheral Htr1b receptor antagonist(s) is a valid
approach in the treatment of postmenopausal osteoporosis.
EXPERIMENTAL PROCEDURES
Mice Generation
To generate osteoblast-specific and gut-specific gene-deficient mice for Lrp5,
Tph1, and Lrp5KI mutations and Htr2b (osb/, gut/), targeting vectors
harboring LoxP sites as well as a floxed neomycin resistance cassette were
electroporated into embryonic stem cells (for details, see Figures S3–S5). ES
cells containing the floxed allele (after NeoR removal) were injected in 129Sv/
EV blastocysts to generate chimeric mice. flox/+ mice were crossed
with a1(I)Col-Cre or Villin-Cre (obtained from the National Cancer Institute
mouse repository) mice to generate osb+/ or gut+/ mice, and their progeny
was intercrossed to obtain osb/ or gut/ mice. Generation of Lrp5/,Cell 135, 825–837, November 28, 2008 ª2008 Elsevier Inc. 835
b-Catfl/fl, b-Cat(ex3)fl/fl,Htr1b/,Htr2a/,Crebfl/fl,Atf4/,Runx2/,Osx/,
Villin-Cre, and a1(I)Col-Cremice was previously reported (Dacquin et al., 2002;
el Marjou et al., 2004; Glass et al., 2005; Heath and Hen, 1995; Kato et al.,
2002; Mantamadiotis et al., 2002; Weisstaub et al., 2006; Yang et al., 2004).
Histology, Protein Expression, and Proliferation Assays
Immunohistochemistry was performed according to standard protocols on
specimens embedded in paraffin and sectioned at 6 mm (Ducy et al., 2000).
In vivo osteoblast proliferation assays (Zymed Laboratories) were performed
on 4-week-old mice injected with BrdU (0.4 mg) and sacrificed 4 hr later. Static
and dynamic histomorphometric analyses were performed on vertebral
column specimens collected from 3-month-old mice using undecalcified
sections according to standard protocols using the Osteomeasure analysis
system (Osteometrics). Six to 12 animals were analyzed for each group.
Cell Cultures and Bioassays
Primary osteoblasts were cultured as previously described (Ducy et al.,
2000). Drug treatments were performed in 0.1% FBS. Cell proliferation was
quantified by BrdU or MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-
lium bromide) assays (Kato et al., 2002). Serum serotonin levels were quanti-
fied by ELISA (serotonin kit, Fitzgerald), whereas serotonin levels in brain
regions were quantified by HPLC as described previously (Mann et al., 1992).
Molecular Studies
RNA isolation and real-time PCR was performed following standard protocols.
Genotypes of all the mice were determined by PCR (see Figures S3–S5). All
primer sequences are available upon request.
Statistical Analysis
Results are given as means ± standard deviations. Statistical analysis was
performed by Student’s t test. For Figures 1–7 and S1–S6, *p < 0.05 and
**p < 0.01 versus WT or control.
SUPPLEMENTAL DATA
Supplemental Data include 11 figures and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(08)01255-5.
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